Clinical Trial Update: Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating intensified 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer with low PSMA expression is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: University of Washington | Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Status: RECRUITING